Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care... Show more
Get AI intraday alerts
A.I. Advisor
published Earnings
OCS is expected to report earnings to rise 17.14% to -43 cents per share on March 22
Q4'26
Est.
$-0.43
Q3'26
Beat
by $0.12
Q2'26
Beat
by $0.23
Q1'26
Beat
by $0.08
Q3'25
Beat
by $0.14
The last earnings report on November 03 showed earnings per share of -37 cents, beating the estimate of -49 cents. With 97.68K shares outstanding, the current market capitalization sits at 415.90M.